{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1436.0","upperLimit":"2098.0","value":"1695.0"},{"comment":"Upper limit of overall survival after long term follow-up was not estimable due low number of participants with the event.","groupId":"OG001","lowerLimit":"2172.0","upperLimit":"NA","value":"2760.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"243"}],"units":"Participants"}],"description":"OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, Vincristine 1.4 mg/m\\^2 and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles Vincristine: Vincristine intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles.","id":"OG000","title":"R-CHOP"},{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, VELCADE 1.3 mg/m\\^2, and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day of a 21 day (3 week) cycle for 6 cycles VELCADE: VELCADE intravenous on Days 1,4,8, and 11 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles.","id":"OG001","title":"VcR-CAP"}],"paramType":"MEDIAN","populationDescription":"The population consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to 107.4 months","title":"Overall Survival (OS) in Long Term Follow-up Period","type":"SECONDARY","unitOfMeasure":"Days"}